Title
Category
Credits
Event date
Cost
Team-Based Case Review: Hepatocellular Carcinoma
  • Hepatocellular Carcinoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Hepatocellular carcinoma (HCC) is associated with poor prognosis, and many patients are diagnosed at an advanced stage. It is essential that all patients be evaluated by a multidisciplinary team prior to treatment initiation.
Advances in Treatment of Recurrent Ovarian Cancer and Rare Malignant Germ Cell Tumors
  • Ovarian Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
The treatment landscape for ovarian, fallopian tube, and primary peritoneal cancers has significantly evolved in recent years due to new FDA approvals and emerging clinical data on available targeted therapies. Additionally, clinical approach for all uncommon histologies of ovarian cancer including rare malignant germ cell tumors can be variable.
Advances in Head and Neck Cancers: Nasopharyngeal and Oral Cancers
  • Head and Neck Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Managing and preventing sequelae following surgery, radiation therapy (RT), and systemic therapy (e.g., trismus, pain, lymphedema and muscle spasm of the neck, xerostomia, dysphagia, speech and swallowing problems, dental and jaw decay, depression, peripheral neuropathy, hearing loss, renal failure) requires professionals familiar with head and neck cancers. Limited data are available comparing the efficacy of different chemoradiotherapy regimens for squamous cell carcinoma of the head and neck (SCCHN). Immunotherapy options for recurrent/metastatic nasopharyngeal cancer is a rapidly evolving area of research.
Dental Care for Patients with Cancer: What Oncologists Need to Know
  • Head and Neck Cancers
  • Supportive Care Topics
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Multiple dental issues can arise for patients with cancer throughout the continuum of cancer therapy. Clinicians must be familiar with the potential complications that can arise in the oral cavity from cancer treatment modalities in order to assist in the prevention and treatment of dental toxicities.
New Tools for Breast Cancer Risk Assessment
  • Breast Cancer
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
It is important for clinicians to learn about these risk assessment models, understand their limitations and benefits, and determine the best breast cancer risk reduction strategy that can be used for an individual.
Updates in the Management of Biliary Tract Cancers
  • Hepatobiliary Cancers
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
$0.00
The advent of novel targeted agents has led to a shift in the treatment paradigm of advanced biliary tract cancers. In recent years, multiple targeted agents were FDA-approved, including tumor-agnostic agents. As such, molecular profiling has become increasingly useful and can potentially help guide treatment decisions.
Treatment for Pleural and Peritoneal Mesothelioma
  • Mesothelioma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Recent phase 3 clinical trial data suggest that surgery and chemotherapy may lead to worse survival outcomes than chemotherapy alone for certain patients with pleural mesothelioma. Additionally, data on other systemic therapy regimens for the treatment of mesothelioma have been recently published.
Advances in the Treatment of Non-Metastatic Non-Small Cell Lung Cancer
  • Lung Cancers
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Clinicians should be aware of all the available systemic therapy regimens as well as updated guideline recommendations on biomarker testing and treatment to ensure that patients with non-metastatic NSCLC receive the most appropriate treatments.
Newer Approaches to Treatment of Bladder Cancer
  • Bladder Cancer
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
$0.00
Recent approvals and clinical trial results continue to enhance treatment options for both BCG-resistant non-muscle invasive bladder cancer and locally advanced/metastatic bladder cancer. Clinicians should be knowledgeable in these recent updates as well as understand how to apply them to their clinical practice.
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?
  • Hodgkin Lymphoma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Novel agents such as antibody-drug conjugates and immune checkpoint inhibitors have become part of front-line treatment recommendations for advanced stage classic Hodgkin lymphoma over the last several years, allowing for reduction in toxicities such as pulmonary toxicity associated with bleomycin and secondary cancer risk from agents such as procarbazine.

Pages